shares are trading higher on Monday after B Riley FBR initiated coverage on the company's stock with a Buy rating and announced a $22 price target.
In this case, B. Riley FBR appears to be very optimistic about the prospects for Vaxart's oral COVID-19 vaccine candidate. This experimental vaccine was recently selected by the U.S. government's Operation Warp Speed for funding and inclusion in a preclinical study.
Keep in mind, though, that it's way too soon to know if Vaxart will be successful. In April, the company reported encouraging results for its oral COVID-19 vaccine candidate in preclinical testing. However, the vaccine candidate hasn't advanced to clinical testing yet.
Now what
Vaxart hopes to advance its oral COVID-19 vaccine candidate to a phase 1 study in the second half of 2020, potentially as early as this summer. Until that trial begins, probably the main catalyst for the biotech stock will be the results for preclinical testing of its universal oral flu vaccine candidate. This preclinical testing is being conducted in collaboration with Johnson & Johnson.
www.fool.com/investi...rocketing-today.aspx
The company also raised about $90 million in gross proceeds through at-the-market-facility.
The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus. Geographically all the business activity is functioned through the region of the US.
finance.yahoo.com/ne...igher-192505411.html
Vaxart Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility
The company sold approximately 11.2 million shares at $7.98 per share, the market price at the time of sale.
The additional funds raised through the ATM facility will support the clinical and preclinical development of Vaxart’s product candidates, to conduct clinical trials, to manufacture its products, and for general corporate and working capital purposes.
finance.yahoo.com/ne...gross-173426952.html
In this case, B. Riley FBR appears to be very optimistic about the prospects for Vaxart's oral COVID-19 vaccine candidate. This experimental vaccine was recently selected by the U.S. government's Operation Warp Speed for funding and inclusion in a preclinical study.
Keep in mind, though, that it's way too soon to know if Vaxart will be successful. In April, the company reported encouraging results for its oral COVID-19 vaccine candidate in preclinical testing. However, the vaccine candidate hasn't advanced to clinical testing yet.
Now what
Vaxart hopes to advance its oral COVID-19 vaccine candidate to a phase 1 study in the second half of 2020, potentially as early as this summer. Until that trial begins, probably the main catalyst for the biotech stock will be the results for preclinical testing of its universal oral flu vaccine candidate. This preclinical testing is being conducted in collaboration with Johnson & Johnson.
www.fool.com/investi...rocketing-today.aspx
The company also raised about $90 million in gross proceeds through at-the-market-facility.
The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus. Geographically all the business activity is functioned through the region of the US.
finance.yahoo.com/ne...igher-192505411.html
Vaxart Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility
The company sold approximately 11.2 million shares at $7.98 per share, the market price at the time of sale.
The additional funds raised through the ATM facility will support the clinical and preclinical development of Vaxart’s product candidates, to conduct clinical trials, to manufacture its products, and for general corporate and working capital purposes.
finance.yahoo.com/ne...gross-173426952.html